GlassScriptPhysician profile
William Homan
NPI 1083235295
$16,117.63
in general payments reported to CMS, 2019-2025
35 companies · $3,723 in 2025
The $3,723 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,043 · 2022: $3,517 · 2023: $3,310 · 2024: $2,524 · 2025: $3,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,557.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,702.48 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,515.81 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,340.25 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,168.33 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Alkermes, INC. | $1,119.63 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $840.32 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $802.24 | 2021-2025 | Ingrezza |
| Tris Pharma INC | $799.96 | 2021-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Lundbeck LLC | $774.68 | 2021-2025 | Rexulti |
| Corium, LLC | $659.17 | 2021-2025 | Azstarys |
| Noven Therapeutics, LLC | $576.78 | 2023-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $526.79 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $485.35 | 2021-2025 | Aplenzin, Wellbutrin |
| Validus Pharmaceuticals LLC | $468.56 | 2023-2025 | Equetro, Equetro, Raldesy |
| Axsome Therapeutics, INC. | $408.46 | 2022-2025 | Auvelity, Sunosi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $362.11 | 2022-2025 | Adzenys Xr-Odt, Exxua |
| Ironshore Pharmaceuticals INC. | $354.14 | 2021-2024 | Jornay Pm |
| Eisai INC. | $267.65 | 2021-2022 | |
| Almatica Pharma LLC | $265.71 | 2021-2025 | Loreev Xr, Gralise |
| Janssen Pharmaceuticals, INC | $232.42 | 2021-2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $230.14 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $217.55 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $183.84 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $138.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $134.38 | 2022-2025 | Quviviq, Quviviq |
| Teva Pharmaceuticals USA, INC. | $127.97 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $95.97 | 2021-2022 | |
| Tempus Ai, INC | $77.51 | 2024 | |
| Neuronetics, INC. | $68.55 | 2023-2025 | Neurostar Tms Therapy System |
| Adlon Therapeutics L.P. | $48.74 | 2021 | |
| Acadia Pharmaceuticals INC | $38.67 | 2022-2023 | Nuplazid |
| Biogen, INC. | $30.02 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.34 | 2025 | |
| Noven Pharmaceuticals, INC. | $17.31 | 2023 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $15.11 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Homan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.